collection
MENU ▼
Read by QxMD icon Read
search

Oncology

shared collection
40 papers 25 to 100 followers
https://www.readbyqxmd.com/read/27050207/antiemetic-prophylaxis-for-chemotherapy-induced-nausea-and-vomiting
#1
REVIEW
Rudolph M Navari, Matti Aapro
Chemotherapy-induced nausea and vomiting (chemotherapy-induced emesis) is a common treatment-related side effect that has a detrimental effect on the quality of life of patients with cancer and may lead to dose reductions in or discontinuation of chemotherapy. The development of new antiemetic..
April 7, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27146751/practical-recommendation-for-rash-and-diarrhea-management-in-indian-patients-treated-with-tyrosine-kinase-inhibitors-for-the-treatment-of-non-small-cell-lung-cancer
#2
P Parikh, K Prabhash, R Naik, A K Vaid, C Goswami, S Rajappa, V Noronha, A Joshi, R T Chacko, S Aggarwal, D C Doval
Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available with manageable safety profile, approved worldwide for the treatment of several neoplasms, including lung, breast, kidney and pancreatic cancer as well as gastro-intestinal stromal tumours and chronic myeloid leukaemia. In recent years, management of lung cancer has been moving towards molecular-guided treatment, and the best example of this new approach is the use of the tyrosine kinase inhibitors (TKIs) in patients with mutations in the epidermal growth factor receptor (EGFR)...
January 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/27072247/serum-carcinoembryonic-antigen-levels-predicts-the-efficacy-of-egfr-tki-in-non-small-cell-lung-cancer-harboring-egfr-mutations
#3
Zhang Yanwei, Jin Bo, Lou Yuqing, Li Rong, Zhang Xueyan, Hu Song, Han Baohui
OBJECTIVES: Not all the patients harboring epidermal growth factor receptor (EGFR) mutations have a clinical response after the treatment of EGFR-tyrosine kinase inhibitor (TKI). The purpose of the present study was to find whether the baseline carcinoembryonic antigen (CEA) levels were associated with the efficacy of EGFR-TKI in patients harboring EGFR mutations. MATERIALS AND METHODS: Clinical features, serum tumor marker levels, and survival time were analyzed, retrospectively, in 200 non-small cell lung cancer (NSCLC) patients harboring EGFR mutations treated with EGFR-TKI...
January 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/26997459/redefining-cancer-and-cure
#4
EDITORIAL
Lisa Hutchinson
No abstract text is available yet for this article.
April 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/26995082/fever-of-unknown-origin-in-cancer-patients
#5
REVIEW
A Loizidou, M Aoun, J Klastersky
Fever of unknown origin (FUO) remains a challenging clinical problem, namely in patients with cancer. In cancer patients, FUO may be due to the cancer itself, as it is the case of hematological malignancies; digestive tumors (colon cancer, liver metastases) are significantly associated with FUO and infection can be demonstrated in some cases. Prevention with G-CSF and empirical antimicrobial therapy are essential approaches for the management of FUO in cancer patients. New diagnostic approaches, such as PET imaging, should be further evaluated in cancer patients with FUO...
May 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/26447685/evolutionary-adaptations-to-risk-of-cancer-evidence-from-cancer-resistance-in-elephants
#6
COMMENT
Mel Greaves, Luca Ermini
No abstract text is available yet for this article.
November 3, 2015: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/26335225/relationships-between-cancer-pattern-country-income-and-geographical-region-in-asia
#7
Chirk Jenn Ng, Chin Hai Teo, Nurdiana Abdullah, Wei Phin Tan, Hui Meng Tan
BACKGROUND: Cancer incidence and mortality varies across region, sex and country's economic status. While most studies focused on global trends, this study aimed to describe and analyse cancer incidence and mortality in Asia, focusing on cancer site, sex, region and income status. METHODS: Age-standardised incidence and mortality rates of cancer were extracted from the GLOBOCAN 2012 database. Cancer mortality to incidence ratios (MIRs) were calculated to represent cancer survival...
2015: BMC Cancer
https://www.readbyqxmd.com/read/26204261/the-evolving-landscape-of-her2-targeting-in-breast-cancer
#8
REVIEW
Mark M Moasser, Ian E Krop
The development of human epidermal growth factor receptor 2 (HER2)-targeting agents for the treatment of HER2-amplified breast cancer has dramatically improved outcomes for patients with this disease. The value of HER2 as a therapeutic target encompasses 2 entirely different mechanistic dimensions. The first approach exploits the fact that HER2 is clearly a disease-driving oncogene to deliver HER2 kinase inhibitors, apparently a highly rational approach to the treatment of HER2-amplified cancers. However, the functionally relevant HER2-HER3 complex has proven much more difficult to inhibit than had been anticipated, and because of its modest efficacy, the HER2 inhibitor lapatinib is currently used predominantly in combinations and in very advanced stages of disease...
November 2015: JAMA Oncology
https://www.readbyqxmd.com/read/26255745/management-of-breast-cancer-in-very-young-women
#9
REVIEW
Shoshana M Rosenberg, Ann H Partridge
Breast cancer is the leading cause of cancer-related deaths in women age 40 and younger in developed countries, and although generally improving, survival rates for young women with breast cancer remain lower than for older women. Young women are more likely to develop more aggressive subtypes of breast cancer (more triple negative and more Human Epidermal Growth Factor Receptor 2 [HER2]-positive disease) and present with more advanced stage disease. Previous research has demonstrated that young age is an independent risk factor for disease recurrence and death, although recent data suggest this may not be the case in certain tumor molecular subtypes...
November 2015: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/26274393/risk-of-severe-acute-exacerbation-of-chronic-hbv-infection-cancer-patients-who-underwent-chemotherapy-and-did-not-receive-anti-viral-prophylaxis
#10
Chih-An Shih, Wen-Chi Chen, Hsien-Chung Yu, Jin-Shiung Cheng, Kwok-Hung Lai, Jui-Ting Hsu, Hui-Chun Chen, Ping-I Hsu
BACKGROUND: Reactivation of HBV replication with an increase in serum HBV DNA and alanine aminotransferase (ALT) activity has been reported in 20-50% of hepatitis B carriers undergoing cytotoxic chemotherapy for cancer treatment. Manifestation of HBV reactivation ranges from asymptomatic self-limiting hepatitis to severe progressive hepatic failure and fatal consequences. AIM: To investigate the risk of severe acute exacerbation of chronic HBV infection in HBsAg-positive cancer patients with solid tumors or hematological malignancies who underwent chemotherapy without antiviral prophylaxis...
2015: PloS One
https://www.readbyqxmd.com/read/26243882/pancreatic-cancer-current-management-and-treatment-strategies
#11
REVIEW
Tamara M H Gall, Maria Tsakok, Harpreet Wasan, Long R Jiao
The 5-year survival of patients with pancreatic cancer is poor and, despite oncological advances over the past two decades, has not significantly improved. However, there have been several surgical and oncological advances which have improved morbidity and mortality in surgery and more efficacious chemotherapy regimens, resulting in a better patient experience and an increase in survival by a number of months. Most patients have a tumour at the head of the pancreas and those with resectable disease undergo a pancreaticoduodenectomy, which can be performed laparoscopically...
October 2015: Postgraduate Medical Journal
https://www.readbyqxmd.com/read/26256762/urine-test-can-detect-early-stage-pancreatic-cancer
#12
Sanjeet Bagcchi
No abstract text is available yet for this article.
September 2015: Lancet Oncology
https://www.readbyqxmd.com/read/25792242/why-are-cancer-drugs-so-expensive-in-the-united-states-and-what-are-the-solutions
#13
REVIEW
Hagop Kantarjian, S Vincent Rajkumar
High cancer drug prices are a worsening trend in cancer care and are affecting patient care and our health care system. In the United States, the average price of cancer drugs for about a year of therapy increased from $5000 to $10,000 before 2000 to more than $100,000 by 2012, while the average household income has decreased by about 8% in the past decade. Further, although 85% of cancer basic research is funded through taxpayers' money, Americans with cancer pay 50% to 100% more for the same patented drug than patients in other countries...
April 2015: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/25113753/recommendations-for-initial-evaluation-staging-and-response-assessment-of-hodgkin-and-non-hodgkin-lymphoma-the-lugano-classification
#14
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister
The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials groups and cancer centers...
September 20, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26037796/the-new-therapeutical-scenario-of-hodgkin-lymphoma
#15
REVIEW
A Stathis, A Younes
Hodgkin lymphoma (HL) remains one of the most curable human cancers, as modern combination chemotherapy and radiation therapy cure ∼ 80% of patients. Over the last two decades, the major efforts were focused on the development of more intensive front-line regimens for patients with advanced stage HL, decreasing the number of chemotherapy cycles and radiation therapy field and doses for patients with early-stage HL and incorporating positron emission tomography imaging in diagnostic, prognostic, and treatment planning...
October 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26220355/tumour-response-correlates-of-survival-and-clinical-benefit
#16
EDITORIAL
Lisa Hutchinson
No abstract text is available yet for this article.
August 2015: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/26185197/giving-bad-news
#17
COMMENT
Walter F Baile
No abstract text is available yet for this article.
August 2015: Oncologist
https://www.readbyqxmd.com/read/24768112/sorafenib-in-radioactive-iodine-refractory-locally-advanced-or-metastatic-differentiated-thyroid-cancer-a-randomised-double-blind-phase-3-trial
#18
RANDOMIZED CONTROLLED TRIAL
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong, Steven I Sherman, Johannes W A Smit, John Chung, Christian Kappeler, Carol Peña, István Molnár, Martin J Schlumberger
BACKGROUND: Patients with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (DECISION), we investigated sorafenib (400 mg orally twice daily) in patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer that had progressed within the past 14 months...
July 26, 2014: Lancet
https://www.readbyqxmd.com/read/23436835/cancer-of-unknown-primary-sites-what-radiologists-need-to-know-and-what-oncologists-want-to-know
#19
REVIEW
Kyung Won Kim, Katherine M Krajewski, Jyothi P Jagannathan, Mizuki Nishino, Atul B Shinagare, Jason L Hornick, Nikhil H Ramaiya
OBJECTIVE: In this article, we review the role of imaging in cancer of unknown primary site (CUP) diagnosis and management and the utility of immunohistochemistry, serum tumor markers, and molecular profiling in the optimized care of CUP patients. CONCLUSION: With advances in imaging, pathology, and molecular medicine, the diagnosis and management of CUP have evolved into more personalized and site-specific therapies. A multidisciplinary integrated approach among oncologists, pathologists, and radiologists is extremely important...
March 2013: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/26118965/routine-screening-with-ct-not-justified-for-occult-cancer
#20
Sanjeet Bagcchi
No abstract text is available yet for this article.
August 2015: Lancet Oncology
label_collection
label_collection
4740
1
2
2015-07-06 01:05:33
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"